2:08 PM
 | 
Apr 27, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Iclaprim: Ph III REVIVE-1 data

Top-line data from the double-blind, international Phase III REVIVE-1 trial in 598 patients with ABSSSIs showed that 80 mg IV iclaprim every 12 hours for 5-14 days met the primary endpoint of non-inferiority to vancomycin in early clinical response, defined as the proportion of patients achieving a ≥20% reduction in lesion area at early time point 48-72 hours after the start of treatment (80.9% vs. 81%). The non-inferiority margin was 10%. Iclaprim was also non-inferior to vancomycin...

Read the full 364 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >